Watching MCKESSON CORP? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAI Executive Summary
AI-powered analysis of 10-Q filing content
McKesson's Q1 FY2027 10-Q shows continued aggressive capital return via share repurchases (~$2.7B in the quarter) alongside a new $5.0 billion buyback authorization approved in April 2026, while the company maintains a Stockholders' Deficit position. Segment reporting was restructured in FY2026 into four segments (North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions), and management reaffirmed no material changes to previously disclosed risk factors. A credit agreement amendment for McKesson Medical-Surgical Top Holdings suggests ongoing debt management activity in that subsidiary.
Red Flags Detected (3)
Company reports a 'Stockholders' Deficit' (negative equity) rather than stockholders' equity, indicating liabilities exceed assets on a book basis
Continued heavy share repurchase activity ($2.7B+ in quarter, $5B new authorization) potentially prioritizing capital return over deleveraging or reinvestment
Amendment to Term B Loan credit agreement for McKesson Medical-Surgical Top Holdings subsidiary suggests refinancing or covenant adjustments were necessary
Key Takeaways
No material changes disclosed to risk factors from the FY2026 Annual Report
Disclosure controls and internal controls over financial reporting deemed effective with no material changes during the quarter
3 more takeaways
Filing Overview
What This Means
Quarterly Report: Interim filing with unaudited financial data for the quarter.